Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
10.84
-0.49 (-4.32%)
At close: Aug 28, 2025, 4:00 PM
11.06
+0.22 (2.03%)
After-hours: Aug 28, 2025, 4:00 PM EDT
Aligos Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts that cover Aligos Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $60, which forecasts a 453.51% increase in the stock price over the next year. The lowest target is $50 and the highest is $70.
Price Target: $60 (+453.51%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aligos Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 1 | 1 | 1 | 1 | 1 | 2 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +361.25% | Aug 18, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $70 | Strong Buy | Reiterates | $70 | +545.76% | Mar 31, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $75 → $70 | Strong Buy | Maintains | $75 → $70 | +545.76% | Mar 11, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +591.88% | Nov 7, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +591.88% | Oct 23, 2024 |
Financial Forecast
Revenue This Year
2.24M
from 3.95M
Decreased by -43.12%
Revenue Next Year
2.89M
from 2.24M
Increased by 28.79%
EPS This Year
-8.77
from -20.94
EPS Next Year
-7.66
from -8.77
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 4.2M | 4.7M | |||
Avg | 2.2M | 2.9M | |||
Low | 1.3M | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 6.5% | 110.6% | |||
Avg | -43.1% | 28.8% | |||
Low | -67.7% | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -8.23 | -5.21 | |||
Avg | -8.77 | -7.66 | |||
Low | -9.48 | -9.72 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | |||
Avg | - | - | |||
Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.